Drug Trial Radar · NCT05164055
Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17
Actual
Start
Jul 11, 2022
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This long-term open label safety and efficacy study is intended to follow up, and to provide post-trial access to ERT with avalglucosidase alfa to patients with Pompe disease in France who have completed Study EFC14028, LTS13769, or ACT14132, from market authorization until the conclusion of negotiations of avalglucosidase alfa in France under the standard reimbursement framework on each indication independently, infantile (IOPD) and late (LOPD), or until June 2027, whichever comes first. \- Study visit frequency: every 2 weeks
Conditions
- Glycogen Storage Disease Type II
Interventions
Avalglucosidase alfa (GZ402666)Drug
Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AE), treatment-emergent adverse events (TEAE), including infusion associated reactions (IAR) and deathTime frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 2500004
Bordeaux, France
Investigational Site Number : 2500005
Brest, France
Investigational Site Number : 2500008
Clermont-Ferrand, France
Investigational Site Number : 2500009
Lille, France
Investigational Site Number : 2500003
Lyon, France
Investigational Site Number : 2500001
Marseille, France
Investigational Site Number : 2500006
Nantes, France
Investigational Site Number : 2500007
Nice, France
Investigational Site Number : 2500002
Paris, France
Investigational Site Number : 2500010
Paris, France
Investigational Site Number : 2500011
Tours, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.